Zentalis Pharmaceuticals Inc
Suletud
3.59 -6.75
Ülevaade
Aktsiahinna muutus
24h
Min
3.42
Max
3.79
Sissetulek | -136K -35M |
|---|---|
Aktsiakasum | -0.503 |
Töötajad | 106 |
EBITDA | -619K -38M |
Soovitused | Osta |
|---|---|
12 kuu keskmine prognoos | +91.26% upside |
Järgmine tulemuste avaldamine | 4. aug 2026 |
|---|
Turukapital | -11M 283M |
|---|---|
Eelmine avamishind | 10.34 |
Eelmine sulgemishind | 3.59 |
Zentalis Pharmaceuticals Inc Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Seotud uudised
Võrdlus sarnastega
Hinnamuutus
Zentalis Pharmaceuticals Inc Prognoos
Hinnasiht
By TipRanks
91.26% tõus
12 kuu keskmine prognoos
Keskmine 7 USD 91.26%
Kõrge 10 USD
Madal 4 USD
Põhineb 7 Wall Streeti analüütiku instrumendi Zentalis Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.
Finantsandmed
Müügi- ja halduskulud
Tegevuskulud
Maksueelne kasum
Müük
Müügikulu
Brutokasum müügist
Intressikulud võla pealt
EBITDA
Ärikasum
$
Ettevõttest Zentalis Pharmaceuticals Inc
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.
